BCM
VRTX icon

Bronte Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Bronte Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-19,856
Closed -$9.23M – 25
2024
Q3 		$9.23M Buy
19,856
+37
+0.2% +$17.8K 0.75% 19
2024
Q2 		$9.29M Sell
19,819
-798
-4% -$346K 0.73% 20
2024
Q1 		$8.62M Sell
20,617
-143
-0.7% -$60.5K 0.7% 23
2023
Q4 		$8.45M Buy
+20,760
New +$7.67M 0.75% 22

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Bronte Capital Management's VRTX Position: Q4 2024 in Review

Bronte Capital Management sold out of Vertex Pharmaceuticals (VRTX) in Q4 2024, closing a stake of 19,856 shares — an estimated $9.23M sold.

Bronte Capital Management first reported a position in VRTX in Q4 2023 and held it in 4 quarters. The position peaked at $9.29M in Q2 2024. 1,558 funds tracked by Wall St. Rank hold VRTX as of Q4 2024.

  • Bronte Capital Management reported no remaining Vertex Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Bronte Capital Management sold 19,856 Vertex Pharmaceuticals shares in Q4 2024, an estimated $9.23M.
  • Bronte Capital Management first reported a position in Vertex Pharmaceuticals in Q4 2023 and held it in 4 quarters.
  • Bronte Capital Management's Vertex Pharmaceuticals position peaked at $9.29M in Q2 2024.
  • 1,558 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2024.

Based on Bronte Capital Management's 13F filing for Q4 2024, filed 10 Feb 2025.